Metropolis Healthcare has approved the issuance of bonus equity shares at a ratio of 3:1, marking a significant corporate action for the healthcare diagnostics company.

Bonus Share Details

The approved bonus issue will provide shareholders with substantial additional equity holdings in the company.

Impact on Shareholders

Under this bonus share scheme, existing shareholders will receive three additional equity shares for every one share they currently hold. This corporate action will increase the total number of shares outstanding while maintaining the proportional ownership structure for all shareholders.

The bonus issue represents a method of rewarding shareholders by capitalizing reserves and distributing additional shares without requiring any payment from investors. This action typically makes shares more affordable and accessible to a broader range of investors while maintaining the overall market capitalization of the company.

Metropolis Healthcare Limited announced its Q3FY26 quarterly results for the quarter ended December 31, 2025, demonstrating robust financial performance alongside significant corporate developments. The diagnostic services company's Board of Directors approved comprehensive quarterly results and strategic initiatives during their meeting held on February 4, 2026.

Strong Financial Performance

The company delivered impressive consolidated financial results with revenue reaching ₹4,059.10 crores compared to ₹3,227.67 crores in the corresponding quarter of the previous year, marking substantial 26% year-on-year growth. Consolidated net profit demonstrated strong momentum at ₹420.87 crores versus ₹314.75 crores in the year-ago quarter, representing a robust 34% increase.

Organic Business Performance

The company's organic business, excluding recent acquisitions, demonstrated exceptional performance with revenue growth of 15% year-on-year. EBITDA margin expanded significantly to 25.0%, up 280 basis points year-on-year, reflecting operating leverage, productivity gains, and sustained efficiency initiatives. The organic business delivered consistent, high-quality growth with sharp margin expansion throughout the nine-month period.

Major Corporate Developments

The Board of Directors approved several significant strategic initiatives during their meeting. Most notably, they recommended a bonus issue of equity shares in the proportion of 3:1, meaning shareholders will receive 3 fully paid-up equity shares of face value INR 2 each for every 1 existing share held. The bonus issue is subject to members, statutory and regulatory approvals, with the record date to be announced in due course.

Regulatory Filing and Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company filed its investor presentation for the quarter ended December 31, 2025, on February 04, 2026. The presentation, signed by Kamlesh C Kulkarni, Head Legal & Secretarial, has been uploaded on the company's website at www.metropolisindia.com and provides comprehensive insights into the company's Q3FY26 performance.

Business Division Sale

The company also approved the execution of a Business Transfer Agreement for the sale of its External Quality Assessment Services Business (EQAS Division) to Metropolis Quality Solutions Private Limited, a wholly owned subsidiary. The slump sale transaction is valued at up to INR 1.25 crores, subject to closing adjustments, and will be completed within 6 months subject to regulatory approvals.

The meeting commenced at 11:15 AM IST and concluded at 3:40 PM IST, with comprehensive discussions on quarterly performance and strategic initiatives that position the company for continued growth in the diagnostic services sector.